Abstract 2060: The exploratory analysis of dysregulated transcription factor FOXC1 in pan-cancer

Abstract

Abstract FOXC1 is a transcription factor that is reported to play a key role in the development of cancer. For example, we showed that epigenetic dysregulation of FOXC1 is associated with meningioma progression. Moreover, we reported that FOXC1 is overexpressed in drug-resistant bladder cancer cells. To further characterize the molecular mechanisms of FOXC1 in carcinogenesis of different cancer types, we analyzed DNA-seq and RNA-seq datasets of over 30 cancer types generated from The Cancer Genome Atlas (TCGA) and Oncology Research Information Exchange network (ORIEN) consortia, using cBioportal. cBioportal is a tool that is used to visualize and analyze large-scale cancer genomic data. When we analyzed whole exome sequencing and DNA array datasets to search genetic alterations such as mutation, amplification, and deletion events that occur in the FOXC1 gene, we revealed that over 10 cancer types have genetic alterations. By analyzing RNA sequencing datasets through the cBioportal, we found that more than 10 cancer types have overexpression of FOXC1. Unlike TCGA, ORIEN has generated whole exome sequencing and RNA sequencing datasets from cancer patients who are treated. We are currently in the process of analyzing ORIEN data to determine FOXC1 alterations and its association with drug resistance in different cancer types. Moreover, we are evaluating the relationship between FOXC1 dysregulation and cancer patient survival. Overall, this analysis will denote the key role that FOXC1 plays in different cancer types and supply valuable knowledge for drug resistance. Citation Format: Alanna Brown, Zexun Wu, Huan Cao, Sara M. Falzarano, Sarah G. Buxbaum, Suhn K. Rhie. The exploratory analysis of dysregulated transcription factor FOXC1 in pan-cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2060.